Reyon Pharmaceutical Co Ltd (KO:102460) — Market Cap & Net Worth
Market Cap & Net Worth: Reyon Pharmaceutical Co Ltd (102460)
Reyon Pharmaceutical Co Ltd (KO:102460) has a market capitalization of $122.80 Million (₩181.21 Billion) as of June 19, 2026. Listed on the KO stock exchange, this Korea-based company holds position #18508 globally and #846 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Reyon Pharmaceutical Co Ltd's stock price ₩9880.00 by its total outstanding shares 18340991 (18.34 Million). Review 102460 total debt and obligations to assess the company's total debt and financial obligations.
Reyon Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Reyon Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $313.77 Million to $122.80 Million (-6.31% CAGR).
Reyon Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Reyon Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Reyon Pharmaceutical Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.04x
Reyon Pharmaceutical Co Ltd's market cap is 0.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $243.90 Million | $121.85 Billion | $10.70 Billion | 0.00x | 0.02x |
| 2017 | $238.33 Million | $126.25 Billion | $12.89 Billion | 0.00x | 0.02x |
| 2018 | $160.15 Million | $122.99 Billion | $1.34 Billion | 0.00x | 0.12x |
| 2019 | $188.55 Million | $131.56 Billion | $5.94 Billion | 0.00x | 0.03x |
| 2020 | $268.26 Million | $130.03 Billion | $3.84 Billion | 0.00x | 0.07x |
| 2021 | $434.69 Million | $142.80 Billion | $5.54 Billion | 0.00x | 0.08x |
| 2022 | $266.55 Million | $154.04 Billion | $7.43 Billion | 0.00x | 0.04x |
| 2023 | $205.58 Million | $151.07 Billion | $3.58 Billion | 0.00x | 0.06x |
| 2024 | $159.59 Million | $148.30 Billion | $4.15 Billion | 0.00x | 0.04x |
Competitor Companies of 102460 by Market Capitalization
Companies near Reyon Pharmaceutical Co Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Reyon Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Reyon Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Reyon Pharmaceutical Co Ltd's market cap moved from $313.77 Million to $ 122.80 Million, with a yearly change of -6.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩122.80 Million | -8.35% |
| 2025 | ₩133.99 Million | -16.04% |
| 2024 | ₩159.59 Million | -22.37% |
| 2023 | ₩205.58 Million | -22.87% |
| 2022 | ₩266.55 Million | -38.68% |
| 2021 | ₩434.69 Million | +62.04% |
| 2020 | ₩268.26 Million | +42.28% |
| 2019 | ₩188.55 Million | +17.73% |
| 2018 | ₩160.15 Million | -32.80% |
| 2017 | ₩238.33 Million | -2.28% |
| 2016 | ₩243.90 Million | -22.27% |
| 2015 | ₩313.77 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Reyon Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $122.80 Million USD |
| MoneyControl | $122.80 Million USD |
| MarketWatch | $122.80 Million USD |
| marketcap.company | $122.80 Million USD |
| Reuters | $122.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more